Actemra Looks Promising in Scleroderma

Author: Nancy Walsh
Date Published: April-2015
Source: MedPage Today

Encouraging results were seen for tocilizumab (Actemra) in the treatment of diffuse systemic sclerosis (SSc) in a proof-of-concept study, an investigator reported here. At 24 weeks, a numerically favorable response was seen on modified Rodnan skin scores among patients randomized to tocilizumab compared with those receiving placebo, with changes of -3.9 units versus -1.2 units, for a difference of -2.70 (95% CI -5.85 to 0.45, P=0.09), according to Christopher P. Denton, MBBS, of University College London.